34 results about "Oncostatin M" patented technology

The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.

Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

This invention discloses a method for producing liver cells by inducing haemopoietic stem cells in vitro, comprising: inoculating the haemopoietic stem cells or CD34+ cells into the culture media containing embryonic bovine serum, human stem cell factor, human interleukins 3(IL-3), interleukins 6(IL-6), human liver cell growth factor, human epidermal growth factor(EGF), human acdic fibroblast growth factor, human basic fibroblast growth factor(bFGF), human leukemia inhibitory factor(LIF) and oncostatin M(OSM), and inducing the producing of liver cells in vitro. By applying the method of this invention to induce liver cells from the haemopoietic stem cells, it can acquire a high proportion of liver cells in the culture with good effects.

This disclosure provides methods for preparing hepatocytes from mesenchymal stem cells by culturing in a first culture media comprising hepatocyte growth factor and a second culture media comprising oncostatin-M. The disclosure also provides the MSC-derived hepatocytes produced by these methods and both in vivo and in vitro uses for these MSC-derived hepatocytes.

Cytokine oncostatin M nucleic acids from Cynomolgus monkey are useful for expression of oncostatin M proteins that are functional homologs of human oncostatin M. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of oncostatin M, the generation and testing of oncostatin M modulators and related activities.

The invention relates to methods of treating chronic intestinal inflammation and/or inflammatory bowel disease by administering an antagonist of oncostatin-M (OSM) and/or OSM receptor-β (OSMR). The invention also relates to methods for diagnosing or prognosing chronic intestinal inflammation and/or inflammatory bowel disease in an individual and for predicting whether or not an individual will respond to an anti-TNFα therapy. The methods comprise measuring OSM and/or OSMR in the individual.

The invention relates to the use of oncostatin M (OSM), an OSM receptor (OSMR) agonist, or a combination of OSM or a OSMR agonist with an interferon type I; in the manufacture of a medicament for enhancing the immunostimulatory activity of epithelial cells in a human.

The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

The invention discloses an artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and a biological product of such artificial polypeptide. The artificial polypeptide is a polypeptide containing an amino acid sequence shown in formula (IV): LGENQPDAK(Xa)PCFQEDPMA(Xb)GTDCTLMEIWN, (IV), wherein each of Xa and Xb is selected from M, Y, L, V, W or E. Professionals in the field know that a strong ability to induce the bone mesenchymal stem cells to differentiate into the hepatic cells is achieved in case of combination of acidic fibroblast growth factor, hepatocyte growth factor and oncostatin M, and after induced culture for 14 days, alpha fetal protein mRNA and albumin mRNA in the cells are in remarkably positive expression. It is proven that the artificial polypeptide with the same effect is capable of inducing the bone mesenchymal stem cells to differentiate into the hepatic cells, and accordingly the artificial polypeptide can be prepared into the biological product for inducing the bone mesenchymal stem cells to differentiate into the hepatic cells.

It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M.

The present invention relates to a differentiation inducing method comprising: introducing, into human induced pluripotent stem cells, a combination of genes of transcription factors which are possessed by fetal and adult hepatic cells, but are not possessed by human induced pluripotent stem cells; and adhering the human induced pluripotent stem cells to a substrate for monolayer culture in a medium containing a combination of growth-promoting agents for proliferation and differentiation, thereby enabling induction of the differentiation of the human induced pluripotent stem cells in large amounts in a short term, a hepatic progenitor cell produced by the method, and a cell composition for transplantation into the liver comprising the cell. The transcription factors include FOXA2, GATA4, HEX and C/EBPα, and the growth-promoting agents include oncostatin M, an epidermal growth factor, retinoic acid, dexamethasone, insulin, transferrin and a selenite ion.

Trans-differentiation induced by dexamethasone with or without oncostatin M results in cells that are capable of propagating and replicating hepatitis virus. Such trans-differentiated cells are useful for screening drugs that may affect the propagation and replication of hepatitis virus such as hepatitis B virus or hepatitis C virus.

The invention belongs to the technical field of cell biotechnology and bone tissue engineering, and particularly relates to application of oncostatin M in preparation of products for promoting mesenchymal stem cells to be in vitro directionally differentiated into bone cells. Experiments prove that oncostatin M has functions of increasing expression of formed bone differentiation markers ALP, Runx2, OPN and OCN in mRNA and protein level and promoting the mesenchymal stem cells to be differentiated directionally into the bone cells. Application studying of oncostatin M matched with the mesenchymal stem cells in preparation of drugs for treating bone injury provides a material basis for development and preparation of drugs for treating diseases like osteoporosis, fracture bone loss and bone trauma.

A method for culturing hepatocytes involves maintenance, proliferation, and passaging of the hepatocytes. The method includes culturing the hepatocytes in a culture medium, which includes a hepatocyte basic medium; CHIR99021, which is a GSK-3 beta inhibitor at a concentration of 0.5-10 μM, SB 431542 or A83-01, which are RGF beta inhibitors, at a concentration of 0.5-10 μM, N-acetyl-cysteine at a concentration of 0.25-25 mM; and Oncostatin M at a concentration of 1-100 ng/mL There is no exogenous gene introduced into the hepatocytes, and the genetic background of the hepatocytes is not changed.

Disclosed herein are methods for the treatment of an individual having an inflammatory bowel disease (“IBD”). The disclosed methods may include the detection of Oncostatin M (OSM) in a biological sample obtained from an individual having an IBD. The detection of OSM may be used to characterize the individual as a tumor necrosis factor (TNF) inhibitor (TNFi) responder or a TNFi non-responder for selection of appropriate treatment.

The invention provides an application of oncostatin-M as biomarker for preparing sepsis diagnosis reagent. The invention provides a condition that the oncostatin-M can be used as a diagnosis index ofthe sepsis; the oncostatin-M can be used as an index for assessing the severity degree of the sepsis, and the treatment and/or prognosis of the sepsis can be predicted according to the oncostatin-M expression level.

The invention discloses a human nasal mucosa epithelial cell inflammation model induced by oncostatin M combined with lipopolysaccharide as well as a preparation method and application. The model is prepared by a method comprising the following steps: inoculating human nasal mucosa epithelial cells into a culture medium for culturing to obtain human nasal mucosa epithelial cells growing in an adherent manner; replacing the culture medium, adding oncostatin M to culture the human nasal mucosa epithelial cells growing in an adherent manner, and then adding lipopolysaccharide to culture to obtain the model. According to the invention, OSM and LPS are combined to serve as irritants to treat human nasal mucosa epithelial cells HNEpC for the first time, OSM serving as a cell factor can destroy a barrier function of the epithelial cells, so that LPS binds to an intracellular receptor of the LPS to initiate an inflammatory reaction, as an induction condition, to construct a more effective and stable in-vitro nasal cavity inflammation model; and the model can be used to more truly, comprehensively and accurately reflect screening of nasal cavity medicine raw materials and products and evaluation of anti-inflammatory effects.

An object of the present invention is to provide a method for differentiating mesodermal cells into mesothelium cells. The present invention provides a method for producing mesothelial cells, including a first culturing step of culturing mesodermal cells in a medium containing basic fibroblast growth factor (bFGF) and oncostatin M.